Literature DB >> 25427560

Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia.

U Schnetzke1, B Spies-Weisshart1, O Yomade1, M Fischer1, T Rachow1, K Schrenk1, A Glaser2, M von Lilienfeld-Toal1, A Hochhaus1, S Scholl1.   

Abstract

Infectious complications continue to be one of the major causes of morbidity and mortality in patients with acute myeloid leukemia (AML). Several single-nucleotide polymorphisms (SNPs) of Toll-like receptors (TLRs) can affect the genetic susceptibility to infections or even sepsis. We sought to investigate the impact of different SNPs on the incidence of developing sepsis and pneumonia in patients with newly diagnosed AML following induction chemotherapy. We analyzed three SNPs in the TLR2 (Arg753Gln) and TLR4 (Asp299Gly and Thr399Ile) gene in a cohort of 155 patients with AML who received induction chemotherapy. The risk of developing sepsis and pneumonia was assessed by multiple logistic regression analyses. The presence of the TLR2 Arg753Gln polymorphism was significantly associated with pneumonia in AML patients (odds ratio (OR): 10.78; 95% confidence interval (CI): 2.0-58.23; P=0.006). Furthermore, the cosegregating TLR4 polymorphisms Asp299Gly and Thr399Ile were independent risk factors for the development of both sepsis and pneumonia (OR: 3.55; 95% CI: 1.21-10.4, P=0.021 and OR: 3.57, 95% CI: 1.3-9.86, P=0.014, respectively). To our best knowledge, this study represents the first analysis demonstrating that polymorphisms of TLR2 and TLR4 influence the risk of infectious complications in patients with AML undergoing induction chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25427560     DOI: 10.1038/gene.2014.67

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  39 in total

Review 1.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

2.  Sepsis in acute myeloid leukaemia patients receiving high-dose chemotherapy: no impact of chitotriosidase and mannose-binding lectin polymorphisms.

Authors:  Anja Klostergaard; Rudi Steffensen; Jens K Møller; Niels Peterslund; Caroline Juhl-Christensen; Ingolf Mølle
Journal:  Eur J Haematol       Date:  2010-03-12       Impact factor: 2.997

3.  R753Q polymorphism inhibits Toll-like receptor (TLR) 2 tyrosine phosphorylation, dimerization with TLR6, and recruitment of myeloid differentiation primary response protein 88.

Authors:  Yanbao Xiong; Chang Song; Greg A Snyder; Eric J Sundberg; Andrei E Medvedev
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

4.  Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracycline-containing regimens.

Authors:  F Rossini; M Verga; P Pioltelli; G Giltri; V Sancassani; E M Pogliani; G Corneo
Journal:  Haematologica       Date:  2000-12       Impact factor: 9.941

5.  Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection.

Authors:  Chantal A A Van der Graaf; Mihai G Netea; Servaas A Morré; Martin Den Heijer; Paul E Verweij; Jos W M Van der Meer; Bart Jan Kullberg
Journal:  Eur Cytokine Netw       Date:  2006-03       Impact factor: 2.737

6.  Type I alveolar epithelial cells mount innate immune responses during pneumococcal pneumonia.

Authors:  Kazuko Yamamoto; Joseph D Ferrari; Yuxia Cao; Maria I Ramirez; Matthew R Jones; Lee J Quinton; Joseph P Mizgerd
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

Review 7.  Recognition of fungal pathogens by Toll-like receptors.

Authors:  M G Netea; C Van der Graaf; J W M Van der Meer; B J Kullberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-18       Impact factor: 3.267

Review 8.  Functional consequences of toll-like receptor 4 polymorphisms.

Authors:  Bart Ferwerda; Matthew Bb McCall; Karlijn Verheijen; Bart-Jan Kullberg; André Jam van der Ven; Jos Wm Van der Meer; Mihai G Netea
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

9.  High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR.

Authors:  Nicolas W J Schröder; Corinna Hermann; Lutz Hamann; Ulf B Göbel; Thomas Hartung; Ralf R Schumann
Journal:  J Mol Med (Berl)       Date:  2003-05-13       Impact factor: 4.599

10.  Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.

Authors:  Pierre-Yves Bochud; Jason W Chien; Kieren A Marr; Wendy M Leisenring; Arlo Upton; Marta Janer; Stephanie D Rodrigues; Sarah Li; John A Hansen; Lue Ping Zhao; Alan Aderem; Michael Boeckh
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more
  13 in total

1.  An endothelial TLR4-VEGFR2 pathway mediates lung protection against oxidant-induced injury.

Authors:  Seyedtaghi Takyar; Yi Zhang; Maria Haslip; Lei Jin; Peiying Shan; Xuchen Zhang; Patty J Lee
Journal:  FASEB J       Date:  2015-12-11       Impact factor: 5.191

2.  Dectin-1 rs3901533 and rs7309123 Polymorphisms Increase Susceptibility to Pulmonary Invasive Fungal Disease in Patients with Acute Myeloid Leukemia from a Chinese Han Population.

Authors:  Mei-Jing Chen; Rong Hu; Xiao-Ying Jiang; Yong Wu; Zhi-Peng He; Jing-Yi Chen; Li Zhan
Journal:  Curr Med Sci       Date:  2019-12-16

3.  Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia.

Authors:  Romy Tober; Ulf Schnetzke; Maximilian Fleischmann; Olaposi Yomade; Karin Schrenk; Jakob Hammersen; Anita Glaser; Christian Thiede; Andreas Hochhaus; Sebastian Scholl
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-18       Impact factor: 4.553

4.  Association between the TLR2 Arg753Gln polymorphism and the risk of sepsis: a meta-analysis.

Authors:  Jun-wei Gao; An-qiang Zhang; Xiao Wang; Zhong-yun Li; Jian-hua Yang; Ling Zeng; Wei Gu; Jian-xin Jiang
Journal:  Crit Care       Date:  2015-11-30       Impact factor: 9.097

Review 5.  The relationship between toll like receptor 4 gene rs4986790 and rs4986791 polymorphisms and sepsis susceptibility: A meta-analysis.

Authors:  Rui Liu; Yuan-Yuan Mo; Hui-Li Wang; Yan Tan; Xiu-Jie Wen; Man-Jing Deng; Hong Yan; Lei Li
Journal:  Sci Rep       Date:  2016-12-13       Impact factor: 4.379

6.  Donor UNC-93 Homolog B1 genetic polymorphism predicts survival outcomes after unrelated bone marrow transplantation.

Authors:  Kaori Uchino; Lam Vu Quang; Shohei Mizuno; Tomohiro Horio; Hidesuke Yamamoto; Ichiro Hanamura; Yoshihisa Kodera; J Luis Espinoza; Makoto Onizuka; Koichi Kashiwase; Yasuo Morishima; Takahiro Fukuda; Noriko Doki; Koichi Miyamura; Takehiko Mori; Eriko Morishita; Shinji Nakao; Akiyoshi Takami
Journal:  Genes Immun       Date:  2021-02-24       Impact factor: 2.676

Review 7.  Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias.

Authors:  Kinga Panuciak; Mikołaj Margas; Karolina Makowska; Monika Lejman
Journal:  Cells       Date:  2022-01-02       Impact factor: 6.600

8.  Recipient and donor PTX3 rs2305619 polymorphisms increase the susceptibility to invasive fungal disease following haploidentical stem cell transplantation: a prospective study.

Authors:  Chen Zhao; Xiao-Su Zhao; Lan-Ping Xu; Xiao-Hui Zhang; Xiao-Jun Huang; Yu-Qian Sun
Journal:  BMC Infect Dis       Date:  2022-03-26       Impact factor: 3.090

9.  Clinical Implication of Toll-Like Receptors (TLR2 and TLR4) in Acute Myeloid Leukemia Patients.

Authors:  Salah Aref; Al Shaimaa Mansoura Abd Elmaksoud; Sherin Abd Elaziz; Mohamed Mabed; Mohamed Ayed
Journal:  Asian Pac J Cancer Prev       Date:  2020-11-01

10.  Association of TLR4 Rs4986791 Polymorphism and TLR9 Haplotypes with Acute Myeloid Leukemia Susceptibility: A Case-Control Study of Adult Patients.

Authors:  Claudia Banescu; Florin Tripon; Anca S Bojan; Adrian P Trifa; Carmen Muntean; George Andrei Crauciuc; Alina Boglis; Marcela Candea; Erzsebet Lazar; Laura Jimbu; Mihaela Iancu
Journal:  J Pers Med       Date:  2022-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.